In Good Company with Nicolai Tangen cover image

HIGHLIGHTS: David Ricks - CEO of Eli Lilly

In Good Company with Nicolai Tangen

CHAPTER

Intro

This chapter explores the recent advancements in GLP-1 medications developed by a leading pharmaceutical company, tracing their historical roots and evolution over the past two decades. The discussion also highlights the potential broader impacts of these drugs, particularly regarding neurological health and metabolic control.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner